Cargando…
Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment
Neuroendocrine (NE) cancers arise from cells within the neuroendocrine system. Chemotherapies and endoradiotherapy have been developed, but their clinical efficacy is limited. The objective of this study was to develop a dual-targeted extracellular vesicles (EV)-delivered combined therapies to treat...
Autores principales: | Si, Yingnan, Guan, JiaShiung, Xu, Yuanxin, Chen, Kai, Kim, Seulhee, Zhou, Lufang, Jaskula-Sztul, Renata, Liu, X. Margaret |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696983/ https://www.ncbi.nlm.nih.gov/pubmed/33187322 http://dx.doi.org/10.3390/pharmaceutics12111079 |
Ejemplares similares
-
Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy
por: Si, Yingnan, et al.
Publicado: (2020) -
Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma
por: Chen, Kai, et al.
Publicado: (2022) -
Anti-SSTR2 Antibody-drug Conjugate for Neuroendocrine Tumor Therapy
por: Si, Yingnan, et al.
Publicado: (2020) -
2018 Synaptic vesicle 2 receptors as a novel targets for
neuroendocrine cancer therapy
por: Jaskula-Sztul, Renata, et al.
Publicado: (2018) -
Antibody–Drug Conjugate to Treat Meningiomas
por: Chen, Kai, et al.
Publicado: (2021)